Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817531 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients
A Phase 2 study, sponsored by Baylor Breast Care Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00817531 is a Phase 2 study that was terminated before completion, run by Baylor Breast Care Center. The registered enrollment target is 22 participants.
The verdict
NCT00817531, a Phase 2 study, was terminated before completion, sponsored by Baylor Breast Care Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
We want to learn if dasatinib will make triple negative breast cancers smaller. We also hope that we can learn more about what makes triple negative breast cancers grow. We believe this information will help us to predict which patients will benefit from taking this drug or other drugs like it. This study is a "neoadjuvant study", which means that it is only open to women who have not had any treatment for their breast cancer. Neoadjuvant studies allow the study doctor to look at how the cells in your cancer change after taking the study medication. This will help us to understand whether or not dasatinib is an effective treatment for breast cancer. It will also help us to learn more about triple negative breast cancer and how to treat it.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00817531
The ClinicalTrials.gov registry entry for NCT00817531 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Breast Care Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT00817531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00817531 about?
NCT00817531 is a clinical study titled "Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients". We want to learn if dasatinib will make triple negative breast cancers smaller. We also hope that we can learn more about what makes triple negative breast cancers grow. We believe this information will help us to predict which patients will benefit from taking this drug or other drugs like it. Thi...
What is the current status of trial NCT00817531?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2008-12. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00817531?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00817531?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.